Screener
Viridian Therapeutics, Inc. VRDN Business Segments — Total share-based compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|---|---|
| Segment research and development expense (a) | $64,189 | $81,401 | $135,933 | $152,439 |
| Segment selling, general and administrative expense (a) | 45,262 | 14,483 | 76,317 | 27,047 |
| Share-based compensation expense (see Note 11) | 16,984 | 10,844 | 30,374 | 21,064 |
| Total operating expenses, excluding depreciation expense | 126,435 | 106,728 | 242,624 | 200,550 |
| License revenue | 180 | — | 186 | — |
| Other items (b) | 504 | (5,993) | (10,790) | (12,903) |
| Consolidated net loss | $127,119 | $100,735 | $232,020 | $187,647 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense?
- Viridian Therapeutics, Inc. (VRDN) reported business segments — total share-based compensation expense of $16.98M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense changed year-over-year?
- Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense increased by 56.6% year-over-year, from $10.84M to $16.98M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense?
- Over 3 years (2022 to 2025), Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense has grown at a 30.9% compound annual growth rate (CAGR), from $19.77M to $44.3M.
- What does business segments — total share-based compensation expense mean?
- This metric represents the total non-cash expense recognized for equity-based awards granted to employees and directors within the business segment. It serves as a measure of the cost of talent retention and incentive alignment through stock-based compensation. Investors track this to understand the impact of equity dilution and non-cash compensation on the segment's overall financial performance.
Ask your AI about Viridian Therapeutics, Inc.'s business segments — total share-based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude